Tumours progress despite being infiltrated by tumour-specific effector T cells 1 . Tumours contain areas of cellular necrosis, which are associated with poor survival in a variety of cancers 2 . Here, we show that necrosis releases intracellular potassium ions into the extracellular fluid of mouse and human tumours, causing profound suppression of T cell effector function. Elevation of the extracellular potassium concentration ([K + ] e ) impairs T cell receptor (TCR)driven Akt-mTOR phosphorylation and effector programmes.
mouse and human tumours (Fig. 1a, b and Extended Data Fig. 1a ) but not in extracellular fluid isolated from healthy tissues (Extended Data Fig. 1b) . We also observed a correlation between TIF [K + ] and the density of dying cells within mouse B16 tumours (Fig. 1c ). Additionally, experimental induction of cell death or apoptosis in tumour-derived cell lines increased extracellular potassium concentration ([K + ] e ) ( Fig. 1d and Extended Data Fig. 1c, d) . Thus, we conclude that the extracellular space within tumours contains elevated [K + ] e , which is associated with local cellular apoptosis and necrosis.
We next investigated whether elevated [K + ] e affects T cell function. We found that isotonic elevations in [K + ] e produced dose-dependent suppression of TCR-induced cytokine production ( Fig. 1e , f). Elevated [K + ] e acted independent of tonicity, with other monovalent and divalent ions or inert osmolytes failing to induce similar suppression (Fig. 1f, g and Extended Data Fig. 1e -h). Elevated [K + ] e acutely suppressed T cell activation across a range of signal strengths (Extended Data Fig. 1i ), in the presence or absence of co-stimulation (Extended Data Fig. 1j ), in a non-redundant fashion with tumour-associated coinhibitory signals (Fig. 1h , i and Extended Data Fig. 2a, b ), in CD4 + T H 1 and T H 17 effector subtypes (Extended Data Fig. 2c, d ). However, it had no effect on cellular viability (Extended Data Fig. 2e ). We next isolated endogenous human neoantigen-specific tumour infiltrating lymphocytes (TILs), which have been identified as likely mediators of immunotherapy-induced tumour clearance 9, 16 , and found that interferon-γ (IFNγ ) production by these cells in response to their cognate neoepitope was attenuated by elevated [K + ] e ( Fig. 1j and Extended Data Fig. 2f , g). Elevated [K + ] e also led to suppression of target-specific IFNγ production by T cells genetically engineered to carry a cancer-germline-antigen-specific TCR 17 (Extended Data Fig. 2h ). Thus, our data suggest that elevated [K + ] e acutely limits the function of mouse and human T cells.
To understand the basis of this suppression of effector function, we investigated the effect of elevated [K + ] e on the molecular events driven by TCR engagement. To this end, we briefly activated fluorescenceactivated cell sorting (FACS)-purified mouse CD8 + T cells in the presence or absence of elevated [K + ] and found that elevated [K + ] e reduced the expression of transcripts induced by TCR stimulation (Fig. 2a, b ). Furthermore, gene-set enrichment analysis indicated that elevated [K + ] e suppressed genes induced by TCR signalling, NF-κ B activation, escape from anergy, the adaptive immune response and cytokine pathways (Supplementary Information 1). Collectively, these data suggest that intratumoural cell death produces elevated [K + ] e concentrations that suppress TCR-driven effector programmes.
As elevated [K + ] e acutely suppressed TCR-driven transcriptional events, we investigated whether [K + ] e could affect TCR-induced signal transduction pathways. Given the role of [K + ] e in regulating plasma membrane potential 18, 19 , we initially hypothesized that K + suppressed Letter reSeArCH 5 4 0 | N A t U r e | V O L 5 3 7 | 2 2 s e p t e m b e r 2 0 1 6 TCR activation by inducing cellular membrane depolarization (increased V m ) with subsequent dissipation of the electromotive force driving Ca 2+ entry. However, we could not detect any changes in TCR-induced Ca 2+ flux in the presence of isotonic elevations in [K + ] e (40 mM) ( Fig. 2c and Extended Data Fig. 3a) . Additionally, elevated [K + ] e did not affect the phosphorylation of Zap70, Erk1/2 or PLCγ 1, or global tyrosine phosphorylation, following TCR ligation ( Fig. 2d and Extended Data Fig. 3b, c) . However, elevated [K + ] e did reduce TCR-induced phosphorylation of Akt and serine/threonine residues targeted by Akt ( Fig. 2e-g and Extended Data Fig. 3d ), including mTOR and the ribosomal protein S6 (Fig. 2f, g and Extended Data Fig. 3d ). Suppression of Akt-mTOR signalling by elevated [K + ] e was noticeable at later time points (Extended Data Fig. 3e ), was not replicated by other osmolytes (Extended Data Fig. 4a ) and was apparent in conditions of hypertonic hyperkalaemia (Extended Data Fig. 4b ). Consistent with a role in limiting Akt-mTOR activity 20 , elevated [K + ] e inhibited TCR-induced nutrient consumption (Extended Data Fig. 4c, d ) and CD4 + polarization to effector lineages (Extended Data Fig. 4e , f) and promoted the induction of Foxp3 + CD4 + T cells (Extended Data Fig. 4g ). We therefore conclude that elevated [K + ] e limits TCR-driven effector function via suppression of the Akt-mTOR pathway.
We next aimed to determine how elevated [K + ] e suppresses TCRinduced Akt-mTOR phosphorylation. First, we hypothesized that elevated [K + ] e inhibits PI3K activity. However, elevated [K + ] e had no effect on TCR-induced phosphatidylinositol-3-phosphate (PtdIns3P) accumulation ( Fig. 2h phosphatases. To interrogate cytokine production in the presence of elevated [K + ] e , we used a pharmacologic screening approach to determine whether selected compounds, including inhibitors of cellular phosphatases, might restore effector function in the presence of elevated [K + ] e (Fig. 3a) . Notably, okadaic acid, an inhibitor of the serine/threonine phosphatase PP2A 21 , significantly restored T cell function in the presence of elevated [K + ] e . Moreover, okadaic acid reversed the hypophosphorylation of Akt and S6 caused by elevated [K + ] e ( Fig. 3b and Extended Data Fig. 5a ) in addition to restoring effector function ( Fig. 3c and Extended Data Fig. 5b ). Similarly, genetic disruption of PP2A function by overexpression of a dominant-negative isoform (PP2A_DN) or by short-hairpin-mediated RNA interference against the PP2A subunit Ppp2r2d similarly rescued effector function in the presence of elevated [K + ] e ( Fig. 3c and Extended Data. Fig. 5c, d ). Consistent with the mechanistic involvement of Akt-mTOR hypophosphorylation in the suppression of effector function mediated by elevated [K + ] e , we found that T cells expressing a constitutively active form of Akt (Akt1_CA) exhibited resistance to the inhibitory effects of high [K + ] e ( Fig. 3c and Extended Data Fig. 5e ). Thus, we conclude that elevated [K + ] e drives hypophosphorylation of the Akt-mTOR pathway in a PP2A-dependent manner.
We next aimed to identify the intracellular changes responsible for decreased Akt-mTOR phosphorylation and cytokine production in the presence of elevated [K + ] e . As K + is the principal determinant of pore resting V m (refs 18, 19) , we first investigated whether increased V m in the presence of elevated [K + ] e provided the source of T cell suppression ( Fig. 3d, e ). To this end we tested whether modulation of V m by other means in the presence of low [K + ] e would result in analogous suppression of T cell function. We treated cells with the ionophore gramicidin, which increases V m by forming pores in the plasma membrane permeable to both Na + and K + (Fig. 3f-h ). However, as gramicidin, unlike elevated [K + ] e , increased IFNγ production ( Fig. 3i ), we reasoned that suppression of T cell function by high [K + ] e is independent of the effect of high [K + ] e on V m and rather depends Fig. 7a, b ). T cells chronically exposed to elevated [K + ] e responded to subsequent [K + ] e changes similarly to those cultured in control conditions (Extended Data Fig. 7c-f ), whereas brief exposure to ouabain partially reversed elevations in [K + ] i and T cell suppression in the presence of high [K + ] e ( Fig. 3m and Extended Data Fig. 6h-k) . Together, these data suggest that elevated [K + ] i in the presence of elevated extracellular K + concentrations may result from a combination of augmented Na + ,K + -ATPase function and a relative decrease in K + flow per channel as the dynamically equilibrated chemical gradient between the intracellular and extracellular space, and the absolute reversal potential for K + , is attenuated.
Collectively, our findings suggested that enhancing T cell K + efflux might increase T cell anti-tumour function. Previous investigations of T-cell-intrinsic K + transport, focusing on the voltage-gated potassium channel K v 1.3 encoded by Kcna3 and the calcium-gated potassium channel K Ca 3.1 (Kcnn4), have described dynamic regulation of K + transport in association with T cell activation and differentiation state 22, 23 . Brief re-stimulation of mouse CD8 + effector cells in vitro (Fig. 2b ) revealed acute upregulation of Kcna3 mRNA in addition to dynamic expression of transcripts encoding potassium channels, pumps, and regulatory subunits (Supplementary Information 2). Because Kcna3 can be induced by TCR activation and has a role in T cell function 24 , we hypothesized that enforced expression of Kcna3 might increase K + efflux and thereby increase intratumoural T cell effector function. We found that overexpression of Kcna3 in mouse T cells ( Fig. 4a , b) resulted in lower T cell [K + ] i (Extended Data Fig. 8a ) and imparted resistance to elevated [K + ] e -mediated suppression of T cell function (Extended Data Fig. 8b ). Overexpression or pharmacologic activation of K Ca 3.1 produced a similar gain of function and resistance to K + -mediated suppression (Extended Data Fig. 8c, d) .
To test whether augmented K + efflux improved T cell function in vivo, we transferred TCR-transgenic Pmel-1 CD8 + mouse T cells transduced with Kcna3, or a control retroviral construct, into B16 tumour-bearing mice. First, we noted that Kcna3 overexpression in TILs increased Akt-mTOR activation ( Fig. 4c ) and IFNγ production within tumours ( Fig. 4d ) and, following brief re-stimulation, ex vivo (Extended Data Fig. 8e ), without affecting T cell phenotype or number in response to viral infection (Extended Data Fig. 8f -g).
To extend our observations, we tested whether human TILs from multiple cancer types were suppressed by elevated [K + ] e , or alternative treatments that increase [K + ] i , in a PP2A-dependent manner. Consistently, we found that either elevated [K + ] e or inhibition of endogenous potassium channels with Ba 2+ increased [K + ] i and suppressed effector function in a manner that also required intact PP2A function in human TILs ( Fig. 4e and Extended Data Fig. 9a, b) .
To test whether the gain of function observed as a result of Kcna3 overexpression resulted from increased ion transport, we generated a non-conducting 'pore dead' construct (Kcna3_PD; W389F) 25 . Kcna3_PD failed to alter [K + ] i , cytokine production in vitro (Fig. 4f, g and Extended Data Fig. 9c ) or the effector function of transduced mouse TILs (Extended Data Fig. 9d ). Moreover, only intact Kcna3 resulted in enhanced tumour clearance and host survival in a mouse tumour model ( Fig. 4h, i) . Collectively, these results indicate that augmenting cellular K + efflux can increase the anti-tumour function of adoptively transferred T cells. In this study, we have shown that cell death within tumours is associated with elevated [K + ] e at a level that leads to increased [K + ] i within T cells, silencing of TCR-induced Akt-mTOR phosphorylation and decreased T cell effector function. Although intact PP2A function was required for K + -mediated suppression of T cell function, K + did not directly affect PP2A phosphatase activity (Extended Data Fig. 9e, f ), suggesting that a functional intermediate is involved. Investigations into the function of PP2A have identified several endogenous small molecules and metabolites that can variably affect PP2A to increase or decrease its contextual function 26, 27 . Future experiments will aim to determine whether [K + ] i alters the processing, localization or abundance of metabolites that affect PP2A activity. These findings may also shed light on prior observations that changes in [K + ] i regulate inflammasome activation in macrophages 28 and can control cellular peptide and phospholipid processing 29, 30 .
Finally, we found that elevated [K + ] e suppresses T cell effector function and that anti-tumour T cells reprogrammed to express the potassium transporter Kcna3 exhibited lower [K + ] i and enhanced effector functions in vitro and in vivo. These data identify a tumourinduced ionic checkpoint acting upon T cell effector function (Extended Data Fig. 10a -c) and show that manipulating the intracellular ion concentration of anti-tumour T cells can augment disease clearance, with implications for immune-based therapies for cancer.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 
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MethOdS Study approval. Animal experiments were conducted with the approval of the NCI and NIAMS Animal Use and Care Committees. All NIH cancer patients providing human samples were enrolled in clinical trials approved by the NIH Clinical Center and NCI institutional review boards. Each patient signed an informed consent form and received a patient information form before participation. Mice and cell lines. Pmel-1 (B6.Cg-/Cy Tg [TcraTcrb] 8Rest/J), Rag2 −/− , OT-II (B6.Cg-Tg (TcraTcrb)425Cbn/J), and C57BL/6 mice were obtained from Jackson Laboratory. C57BL/6 male mice of 6-8 weeks of age were used as recipient hosts for adoptive transfer unless otherwise indicated. We crossed Pmel-1 with Ly5.1 mice (B6.SJL-Ptprc a Pepc b /BoyJ) to obtain Pmel-1 Ly5.1 mice. We crossed OT-II with Rag2 −/− to obtain OT-II Rag −/− mice. All mice were maintained under specific pathogen-free conditions. B16 (H-2D b ), a mouse melanoma, transduced as previously described 31 to express glycoprotein 100 (gp100) with human residues at positions 25-27; EGS to KVP. The Mel624 human melanoma-derived cell line was a gift of S.A.R. Platinum-E ecotropic packaging cells were obtained from Cell Biolabs. HLA-A*0201 + NY-ESO-1 + A375 cells were obtained from ATCC. Cell lines were maintained in DMEM with 10% FBS, 1% glutamine and 1% penicillin-streptomycin. Cell line authentication. Platinum-E cells were obtained from Cell Biolabs following authentication and validation as being mycoplasma free. A375 cells were obtained from ATCC following authentication and validation as being mycoplasma free. Mel624 was authenticated as previously described 17 . Authenticated B16 was obtained from the National Cancer Institute Tumour Repository and validated as being mycoplasma free via a PCR-based assay. Statistical analysis. Data were compared using either a two-tailed Student's t-test corrected for multiple comparisons by a Bonferroni adjustment or repeated measures two-way ANOVA, as indicated. Where necessary, the Shapiro-Wilk test was used to test for normality of the underlying sample distribution. Experimental sample sizes were chosen using power calculations with preliminary experiments or were based on previous experience of variability in similar experiments. Samples that had undergone technical failure during processing were excluded from analyses. The Kolmogorov-Smirnov test was used to evaluate the significance between different distributions. For adoptive transfer experiments, recipient mice were randomized before cell transfer. The products of perpendicular tumour diameters were plotted as the mean ± s.e.m. for each data point, and tumour treatment graphs were compared by using the Wilcoxon rank sum test and analysis of animal survival was assessed using a log-rank test. In all cases, P values of less than 0.05 were considered significant. Statistics were calculated using GraphPad Prism 7 software (GraphPad Software Inc.). Electrolyte analysis of serum and interstitial fluid. We used a previously reported method to isolate tissue interstitial fluid via a centrifugation method 6, 14, 15 . Briefly, en bloc tissue was harvested, placed on triple-layered 10-μ m nylon mesh and spun at < 50g for 5 min to remove surface liquid. Next, samples were centrifuged at 400g, a previously validated speed at which intracellular contents are not liberated 14, 15 , for an additional 10 min Flow-through from this step was retained as interstitial fluid and assayed for indicated electrolyte concentrations in a blinded fashion within the NIH Central Clinical Chemistry Laboratory using auto analyser ion selective electrode quantification (Cobas 6000; US Diagnostics) 32 . External solution formulations. Unless otherwise indicated, re-activation of cells in elevated [K + ] e was performed with an isotonic RPMI formulation with an additional 40 mM of potassium for mouse cells and 50 mM for human cells in comparison to the control condition medium. In principal this medium was produced by obtaining a custom formulation of RPMI 1640 from Gibco that was devoid of NaCl. For control conditions, this medium was reconstituted with NaCl to produce a solution equimolar to standard RPMI. Thus, the final inorganic salt concentrations for the control condition were identical to those in RPMI 1640 (Gibco) in mM: NaCl 103.4, NaHC0 3 Generation and activation of effector T cells. In vitro activation of T cells was carried out either by negative enrichment (Miltenyi Biotec) of CD8 + T cells from C57BL/6 mice followed by activation using immobilized anti-CD3 (145-2C11; eBioscience) and anti-CD28 (37-51; eBioscience) along with expansion in culture medium containing IL-2 for 4-5 days, or via isolation of Pmel-1 Ly5.1 mouse whole splenocytes followed by stimulation in vitro with 1 μ M human glycoprotein 100 nine-mer peptide (hgp100 [25] [26] [27] [28] [29] [30] [31] [32] [33] ) peptide and expansion in culture medium containing IL-2 for 4-5 days. For analysis of T cell effector function, these cells were then stimulated on day 4 or 5 of culture in the indicated conditions for 5 h with anti-CD3 and -CD28 without IL-2 in the presence of brefeldin A and monesin (BD Biosciences). For assaying co-inhibitory signalling, during PD-L1-based co-inhibition, PD-L1-IgG2a (R&D) was conjugated along with anti-CD3 and anti-CD28 antibodies (eBioscience) and control IgG2a (R&D) onto M-450 Epoxy Dynabeads (Thermo Fisher) at a ratio of (1:1:2:6) for (anti-CD3:anti-CD28:PD-L1-IgG2a:IgG2a) for a total of 5 μ g ml −1 protein per 2 × 10 6 beads overnight at 4 °C. For comparative control conditions IgG2a was replaced by PD-L1 to control for bead loading. These beads were then incubated with effector CD8 + T cells at a ratio of 1:1 in the indicated conditions for 5 h. For CTLA-4 based co-inhibition, anti-CD3, anti-CD28, and CTLA-4-IgG2a (R&D) or IgG2a (R&D) were coated onto tissue culture-treated 96-well plates at a concentration of 5 μ g ml −1 (in a fashion similar to standard immobilized antibody-based stimulation) for each reagent overnight at 4 °C. For assaying neoantigen specific reactivity, human TILs from NCI-14-C-0062, generated as described below, were re-activated for 5 h with autologous pre-activated B cells that were pulsed with the indicated wild-type or neo-antigen peptides as described below. Transduced human peripheral blood lymphocytes were co-cultured with the A375 patient-derived melanoma tumour line HLA-A* 0201 + and positive for NY-ESO-1 expression 33 , at a ratio of 1 T cell to 3 tumour cells in the presence of brefeldin A and monesin (BD Biosciences) for 5 h. For analysis of human CD8 + TILs from varied histologies in the presence or absence of elevated K + or Ba 2+ , TILs were first grown from tumour fragments cultured in 6,000 IU ml −1 IL-2 in a 1-to-1 mixture of RPMI 1640 and AIM-V, supplemented with 5% in-house human serum 100 μ g ml −1 streptomycin and 100 μ g ml −1 penicillin, 2 mM l-glutamine, 10 μ g ml −1 gentamicin, for approximately 14 days per standard operating GMP protocols practiced by the Surgery Branch 34 . These T cells were then subjected to a rapid expansion protocol (REP) using irradiated peripheral blood mononuclear cells (PBMC) at a ratio of 1 to 300 in the same complete medium with 30 ng ml −1 OKT3 in preparation for subsequent patient transfer. These cells were activated via immobilized anti-CD3 and anti-CD28 in the presence of K + , Ba 2+ , and/or okadaic acid (OA) as indicated. For experiments Naive mouse CD4 + cells were obtained by isolating splenocytes from 6-10 week-old OT-II Rag −/− mice and subjected to negative selection of naive CD4 + T cells (Stemcell Technologies). These naive cells were activated with immobilized anti-CD3 and anti-CD28 (5 μ g ml −1 each) in medium for 2 days followed by an additional 2 days on blank plates with relevant polarizing cytokines present during the entire duration of the 4-day culture: T H 1 conditions (IL-12 10 ng ml −1 or as indicated, R&D Systems) T H 17 conditions (IL-6 (20 ng ml −1 , R&D Systems), human TGF-β 1 (1 ng ml −1 , R&D Systems), anti-IFNγ neutralizing antibodies (10 μ g ml −1 ), IL-1β (10 ng ml −1 ), or iT reg conditions (human TGF-β 1 200 pg ml −1 ) as indicated.
For selected experiments as indicated cells were treated with the PP2A inhibitor okadaic acid at a concentration of 200 nM (mouse CD8 + T cells) or 125 nM (human CD8 + TIL), the ionophore gramicidin (0.75 or 1.5 μ M), the inhibitor of the Na + ,K + -ATPase, ouabain 125 μ M (pre-incubated for 30 min), the K Ca 3.1 activator 1-EBIO (50 μ M), or the ionophore valinomycin (2 μ M). RNA purification, quantitative real-time RT-PCR, RNA-sequencing and bioinformatic analysis. RNA sequencing was performed and analysed as described previously 35 . CD8 + 62 L + C57BL/6 splenocytes were FACS sorted from 6-8-weekold mice in biological triplicate and activated with anti-CD3 and -CD28 for 48 h in IL-2 100 IU ml −1 and cultured in RPMI complete medium for an additional 72 h. Cells were then subjected to ficoll density separation to isolate live cells, placed in complete medium without IL-2 in the presence or absence of elevated [K + ] e , and either re-stimulated with anti-CD3 and -CD28 or kept in complete medium for 2 h with no stimulation (No stim). Cellular RNA was preserved with RNAlater (Qiagen) and purified with the RNeasy Plus Mini Kit (Qiagen). RNA was subsequently used to prepare RNA-seq libraries by using TruSeq SRRNA sample prep kit (FC-122-1001, Illumina) according to the manufacturer's instructions. The libraries were sequenced for 150 bp (paired-end) using a NextSeq500 sequencer Letter reSeArCH (Illumina) . Sequence reads from each cDNA library were mapped onto the mouse genome build mm9 by using TopHat, and the mapped data was then processed by Cufflinks 36 . The obtained data was normalized based on RPKM (reads per kilobase exon model per million mapped reads). To define differentially regulated genes, we used a 1.5-fold change difference between treatment groups. Real-time RT-PCR was performed for genes following cDNA generation by reverse transcription (Applied Biosystems) with primers from Applied Biosystems by Prism 7900HT (Applied Biosystems). Extracellular acidification rate and basal oxygen consumption rate. Oxygen consumption rates (OCR) and extracellular acidification rates (ECAR) were measured following re-stimulation of T cells using anti-CD3/CD28 Dynabeads (Invitrogen) in a 0.8:1 ratio at 37 °C using an XF24 extracellular analyser (Seahorse Bioscience) as previously described 37 in the indicated conditions. OCR and ECAR were measured in XF medium (non-buffered RPMI 1640 containing 25 mM glucose, 2 mM l-glutamine, and 1 mM sodium pyruvate) in a 1:1 mixture with tonicitycontrolled, additive-free standard RPMI 1640 with normal or elevated [K + ] under basal conditions and in response to 1 μ M oligomycin, 2 μ M fluoro-carbonyl cyanide phenylhydrazone (FCCP) or 100 nM rotenone with 1 μ M antimycin A (Sigma). Intracellular cytokine staining, phosphoflow and flow cytometry. Suspensions containing T cells were stained with a fixable live/dead stain (Invitrogen) in PBS followed by surface antibody staining in FACS buffer (PBS with 0.5% BSA and 0.1% sodium azide). For intracellular cytokine staining, cells were stained for intracellular molecules following fixation and permeabilization. For phosphostaining BD PhosFlow reagents were used and fixation and permeabilization protocols were carried out according to the manufacturer's protocols. After washing, cells were stained with antibody-fluorochrome conjugates for the indicated phosphorylated proteins (pZap70 Y319 (BD Biosciences); all other phospho-antibodies were purchased from Cell Signaling). Antibodies for surface staining and intracellular cytokine staining were purchased from BD Biosciences and eBiosciences. For determination of cytoplasmic V m cells were incubated in 2 μ M DiSBAC 4 3 (Invitrogen) in conditions as indicated for 60 min before evaluation. For determination of [K + ] i , cells were loaded with the potassiumsensitive dye Asante Green-4 (TEFLabs) with PowerLoad (Invitrogen) per the manufacturer's protocols. All experiments were conducted on a BD Fortessa flow cytometer (Becton Dickinson) and analysed with FlowJo software. Identification and purification of mutation-specific TILs. Cancer-specific mutations and TILs targeted against those mutations from patients with metastatic melanoma were identified as previously described 38 . Briefly, patients were enrolled on a clinical protocol (NCI-14-C-0062). Whole-exomic sequencing (WES) was performed on tumour tissue and normal peripheral blood cells by Personal Genome Diagnostics (PGDx) and the data were aligned to genome build hg18. A viable metastatic tumour deposit was selected for resection as a source for TILs. The resected en bloc tumour was subjected to mechanical disruption using a GentleMACS Dissociator (Miltenyi Biotec). The bulk tumour digest was cultured in complete medium without IL-2 or other cytokines overnight. The following day CD3 + PD-1 + T cells were FACS sorted using a BD FACSJazz flow cytometer. These sorted T cells were then subjected to a rapid expansion protocol (REP) using irradiated PBMC at a ratio of 1 to 300 in 50/50 medium (1-to-1 mixture of RPMI 1640 and AIM-V, supplemented with 5% in-house human serum, 100 U ml −1 penicillin, 100 μ g ml −1 streptomycin, 2 mM l-glutamine and 10 μ g ml −1 gentamicin), 3,000 IU ml −1 IL-2, and 30 ng ml −1 OKT3 antibody (Miltenyi Biotec) for approximately 14 days. At the conclusion of the first REP T cells were screened and FACS sort-enriched with the BD FACSJazz based on 41BB positivity 38 , against tandem mini-gene (TMG) constructs encoding for tumour specific mutations identified by WES for each patient and tumour, as described above 9, 38, 39 . These enriched neoantigen-specific T cells were then expanded via a second REP. At the conclusion of the second REP T cells were activated with peptide pulsed (at 1:3; effector: target) autologous CD40L-stimulated B cells with either 10 μ g ml −1 of the full length 23-mer mutated or wild peptide (patient A) or 1 μ g ml −1 of the minimal epitope (patients B, C) in the indicated conditions. Retroviral transduction. Platinum-E ecotropic packaging cells (Cell Biolabs) were plated one day before transfections on poly-d-lysine-coated 10-cm plates (Corning) at a concentration of 6 × 10 6 cells per plate. Packaging cells were transfected with 20 μ g of retroviral plasmid DNA encoding MSGV-Thy1.1, MSGV-Kcna3-Thy1.1, MSGV-Kcna3-Thy1.1 (W389F) (referred to as Kcna3_PD) 25, 40 , MSGV-Ppp2r1a(K416E)-Thy1.1 (referred to as PP2A_DN 41, 42 ), MSCV-IRES-Thy1.1 (pMIT), or pMIT Akt1-CA 43 where indicated along with 6 μ g pCL-Eco plasmid DNA using 60 μ l Lipofectamine 2000 in OptiMEM (Invitrogen) for 8 h in antibiotic-free medium. Medium was replaced 8 h after transfection and cells were incubated for a further 48 h. Retroviral supernatants were then collected and spun at 2,000g for 2 h at 32 °C onto 24-well non-tissue-culture-treated plates coated overnight in Retronectin (Takara Bio). For in vivo experiments live cells were isolated via ficoll density separation (Cedarlane) and subjected to positive selection via CD90.1-microbead column enrichment according to the manufacturer's protocol (Miltenyi Biotec) before transfer, yielding a CD8 + T cell population 70-95% Thy1.1 + before transfer. For retroviral transduction of human peripheral blood lymphocytes (PBL) with the NY-ESO-1 TCR, patients with metastatic melanoma on clinical protocol NCI-13-C-0214 were subjected to leukapheresis and the PBL of these patients were transduced with a MSGV1 backbone encoding the NY-ESO-1 mouse-derived TCR as previously described 17 . After primary transduction and culture (10 days), these cells were then further expanded via a REP as described above (days 10-23) and subsequently assayed for target-specific effector function in the indicated conditions. Adoptive cell transfer (ACT) and tumour immunotherapy. For immunotherapy, C57BL/6 were implanted with subcutaneous B16 melanoma (5 × 10 5 cells). At the time of adoptive cell transfer (ACT), 10 days after tumour implantation, mice (n ≥ 5 for all groups) were sub-lethally irradiated (600 cGy), randomized, and injected intravenously with 5 × 10 5 Pmel-1 Ly5.1 cells transduced with controlor Kcna3-expressing retrovirus and received intraperitoneal injections of IL-2 in PBS (6 × 10 4 IU per 0.5 ml) once daily for 3 days starting on the day of cell transfer. Tumours were blindly measured using digital callipers. Tumour size was measured in a blinded fashion approximately every two days after transfer and tumour area was calculated as length × width of the tumour. Mice with tumours greater than 400 mm 2 were killed. The products of the perpendicular tumour diameters are presented as mean ± s.e.m. at the indicated times after ACT. For functional analysis of transferred Pmel-1cells, B16 tumour-bearing mice received Pmel-1 cells as above, and 6-8 days following cell transfer mice were injected with 500 μ l of 0.5 mg ml −1 brefeldin A (Sigma) and 6 h later tumours were harvested and processed for live/dead, surface, fixation, and intracellular staining for direct in vivo IFNγ capture 44 . For ex vivo restimulation, tumours were harvested and processed as above, red cells were lysed with ACK lysis buffer for 2 min at room temperature, then cell suspensions were subjected to live-cell isolation via ficoll density gradient separation (CedarLane) and stimulated in medium containing leukocyte activation cocktail with Golgiplug (BD biosciences) for 4 h at a final concentration of 2 μ l ml −1 . Viral infection and kinetic analysis. For assessing the response of CD8 + T cells to acute viral infection, 5 × 10 5 transduced and Thy1.1 + enriched Pmel-1 Ly5.1 CD8 + T cells were transferred into recipient Thy1.2 Ly5.2 C57BL/6 mice. Immediately following transfer, mice were infected with rhgp100 1 × 10 7 plaque-forming units (PFU). At the indicated time points following transfer, recipient mouse blood was obtained via sub-mandibular venipuncture and analysis for phenotype and enumeration of the congenically identified transferred cells was carried out. T cell receptor (TCR) crosslinking, western blots. As described previously 45 , to induce TCR crosslinking in vitro generated T cells were rested overnight in the absence of IL-2, subsequently subjected to live cell isolation via ficoll density gradient separation and pre-incubated with soluble anti-CD3-and anti-CD28biotin, appropriate surface antibodies and pharmacologic inhibitors where indicated in additive-free RPMI 1640 at 4 °C. Cells were then washed, brought up to 37 °C, and linked via the addition of streptavidin in the indicated conditions. For western blots, at the indicated time points following cross-linking, cells were lysed by the addition of 95 °C 2 × Laemmli sample buffer with 2-mercaptoethanol (Bio-Rad Laboratories) and sonicated for 40 s at 10% intensity before gel loading. For K v 1.3 protein analysis, Thy1.1 + enriched T cells were lysed in 1× RIPA buffer (Thermo Fisher) with protease and phosphatase inhibitors (Roche). Western blotting was performed using TGX reagents (Bio-Rad Laboratories) and protocols on PVDF paper. Following transfer, blots were blocked with 5% BSA then incubated with antibodies against phospho-tyrosine (4G10; EMD Millipore), pAkt-T308, total Akt, β -actin, Akt-substrate, or phospho-threonine with appropriate HRPconjugated or Alexa 647-conjugated secondary antibodies (Cell Signaling Technology) or anti-K v 1.3 (NeuroMab). For HRP-conjugated secondary antibodies blots were developed using chemiluminescence (Thermo Fisher) and gel images were captured with the Gel Doc XRS (Bio-Rad Laboratories). For PI3K activity, cells were fixed at the indicated time points by the 1:1 addition of a mixed lysis solution containing 30 mM HCl, 65% methanol and 30% chloroform, maintained at − 80 °C, then processed and analysed as previously described 46 . T cell receptor induced calcium influx. T cells were isolated and primed as above. Prior to analysis cells were rested in IL-2-free complete RPMI 1640 for at least 8 h. Cells were loaded with 1 μ M Fluo3-AM and 1 μ M Fura Red-AM (Invitrogen) for 30 min at 37 °C in HBSS with Ca 2+ , Mg 2+ and 2% FCS, washed twice and then resuspended in HBSS with anti-CD3-and -CD28-biotin conjugates (eBioscience) and a live/dead stain (Invitrogen). For flow cytometry analysis, samples were resuspended in pre-warmed 37 °C 1:1 mixtures of HBSS and isotonic normokalaemic or hyperkalaemic additive-free RPMI (as described above), a baseline measurement was recorded for 20 s, followed by the addition of streptavidin (Invitrogen) to a final concentration of 20 μ g ml −1 to induce TCR 
